Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liminal Biosciences Inc (LMNL.TO)

Liminal Biosciences Inc (LMNL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Liminal Biosciences Inc 440, Boulevard Armand-Frappier Suite 300 Laval QC H7V 4B4 CAN

P: 450-781-0115

Sector:

Medical

INDUSTRY GROUPING:

TSX Biotechnology

Description:

Liminal Biosciences engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: small molecule therapeutics and plasma-derived therapeutics. The small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.

Key Statistics

Overview:

Market Capitalization, $K 682,931
Shares Outstanding, K 23,628
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 68.69%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -26.59%

Per-Share Information:

Next Earnings Date 08/10/20
Earnings Per Share ttm 3.45
Dividend Payout Ratio 0.00%
Most Recent Split 1-1000 on 07/05/19

LMNL.TO Ratios

Ratio
Price/Earnings ttm 1.28
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -123.54%
Return-on-Assets % -61.09%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 6.87
Book Value/Share N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar